Evidence map›Paper›PMID 32296833›Full record

ArticleThe Biochemical journal2020

Quantitative mapping of binding specificity landscapes for homologous targets by using a high-throughput method.

Lidan Aharon, Shay-Lee Aharoni, Evette S Radisky, Niv Papo

Open access · hybridAbstract read
In one paragraph

Article in The Biochemical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Lidan AharonDepartment of Biotechnology Engineering and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Shay-Lee AharoniDepartment of Biotechnology Engineering and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Evette S RadiskyDepartment of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville 32224, Florida, U.S.A.
Niv PapoDepartment of Biotechnology Engineering and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Ben-Gurion University of the Negev · ILMayo Clinic in Florida · US

Funding

Inhibiting serine protease-induced prostate cancer progressionR01CA154387 · NCI · MAYO CLINIC JACKSONVILLE · PI RADISKY, EVETTE S · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA154387
6 · The paper itself

Abstract

To facilitate investigations of protein-protein interactions (PPIs), we developed a novel platform for quantitative mapping of protein binding specificity landscapes, which combines the multi-target screening of a mutagenesis library into high- and low-affinity populations with sophisticated next-generation sequencing analysis. Importantly, this method generates accurate models to predict affinity and specificity values for any mutation within a protein complex, and requires only a few experimental binding affinity measurements using purified proteins for calibration. We demonstrated the utility of the approach by mapping quantitative landscapes for interactions between the N-terminal domain of the tissue inhibitor of metalloproteinase 2 (N-TIMP2) and three matrix metalloproteinases (MMPs) having homologous structures but different affinities (MMP-1, MMP-3, and MMP-14). The binding landscapes for N-TIMP2/MMP-1 and N-TIMP2/MMP-3 showed the PPIs to be almost fully optimized, with most single mutations giving a loss of affinity. In contrast, the non-optimized PPI for N-TIMP2/MMP-14 was reflected in a wide range of binding affinities, where single mutations exhibited a far more attenuated effect on the PPI. Our new platform reliably and comprehensively identified not only hot- and cold-spot residues, but also specificity-switch mutations that shape target affinity and specificity. Thus, our approach provides a methodology giving an unprecedentedly rich quantitative analysis of the binding specificity landscape, which will broaden the understanding of the mechanisms and evolutionary origins of specific PPIs and facilitate the rational design of specific inhibitors for structurally similar target proteins.

Indexed as

Protein Interaction Domains and MotifsComputational BiologyGene LibraryHigh-Throughput Nucleotide SequencingMatrix Metalloproteinase 1Matrix Metalloproteinase 14Matrix Metalloproteinase 3MutagenesisMutationProtein EngineeringProtein Interaction MappingTissue Inhibitor of Metalloproteinase-2Matrix Metalloproteinase 1Matrix Metalloproteinase 14Matrix Metalloproteinase 3MMP14 protein, humanMMP1 protein, humanMMP3 protein, humanTissue Inhibitor of Metalloproteinase-2metalloproteasesnext-generation sequencingprotease inhibitorprotein engineeringprotein–protein interactions

Identifiers

PMID32296833
PMCPMC7376575
OpenAlexW3016986530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.